68 results about "Haemorrhagic fever" patented technology

The invention relates to a composition for widely treating viral diseases. The composition contains the following raw materials, or extracts of the following raw materials, or derivatives of the extracts of the following raw materials in chemically-acceptable forms, wherein the raw materials include processed products prepared from the raw materials. The constituents of the composition are as follows: 100 parts of Baikal skullcap root, 50-150 parts of radix bupleuri and 50-150 parts of kudzu root; and according to specific circumstances, one or more selected from (but not limited to) the following raw materials can be added on this basis: radix isatidis, honeysuckle flower, Fructus Forsythiae, rhubarb, phellodendron bark, rhizoma anemarrhenae, Cyrtomium fortunei, gardenia, coptis, rhizoma cyperi, fritillaria, balloonflower and licorice root. The composition provided by the invention can be prepared into powder, liquid, paste, granules, capsules or other pharmaceutically-acceptable physical forms. The composition provided by the invention is used for preventing and treating avian influenza, epidemic hemorrhagic fever, epidemic parotitis, nameless hyperpyrexia, Newcastle diseases, swine fever, blue-ear diseases and other multiple human and animal viral diseases characterized by hemorrhage or body temperature rise, and reducing the degree of pathological damage to the body.

The invention discloses an RPA technology-based marburg virus detection kit and an application thereof. An experiment proves that a target gene can be effectively amplified by an RPA primer and a probe of a marburg virus, the specificity reaches 100% and sensitivity is 1*10<2>copies/reaction; and the virus can reach the level equivalent to the sensitivity of fluorescent quantitative PCR, and has no cross reaction with a zaire ebola pseudovirus, a dengue virus, a hemorrhagic fever virus with renal syndrome and a Xinjiang hemorrhagic fever virus nucleic acid. The RPA isothermal amplification system is fast in reaction and wide in temperature range, effective amplification of a target gene can be achieved under the condition of 37-42 DEG C, the method can be used for fast field detection of an infectious nucleic acid of the marburg virus, and an available fast detection method is provided for field screening of a pathogen; and meanwhile, the marburg virus detection kit also has the important significance in prevention of infection transmission of the marburg virus in China and inspection and quarantine in affected areas and entry and exit ports.

The invention relates to a glycyrrhizic acid derivative, preparation thereof and use thereof. The derivative has high water solubility and high storage stability and is suitable to be used in medicaments and health-care products for treating or preventing hepatitis, liver cirrhosis, hemorrhagic fever of liver damage and liver dysfunction syndrome, allergic purpura, psoriasis vulgaris, eczematousdermatitis and the like.

The invention relates to the field of genetic engineering and particularly relates to a preparation method of a rabbit hemorrhagic fever virus empty capsid antigen. The method provided by the invention comprises the following steps: 1) constructing a rhabdovirus transfer carrier containing a rabbit hemorrhagic fever virus capsid protein VP60 gene or an optimized gene, wherein codon optimization is performed according to the codon frequency of bombyx mori; 2) performing cotransfection on the constructed transfer expression carrier and DNA (deoxyribonucleic acid) of rhabdovirus so as to carry out homologous recombination or transposition to further obtain the recombinant rhabdovirus; 3) infecting the recombinant rhabdovirus with the host cells of an insect; and 4) culturing the infected host of the insect to express the corresponding rabbit hemorrhagic fever virus empty capsid antigen, and harvesting and purifying the expressed antigen. By adopting the method provided by the invention, the production cost of the rabbit hemorrhagic fever virus empty capsid antigen can be greatly reduced, and the method has a plurality of advantages of safety, high efficiency, low energy consumption, low cost and the like.

The invention provides horse anti-EBOV (Ebola virus) immune globulin F (ab')2 and a preparation method thereof. The preparation method comprises steps as follows: virus-like particles of a GP gene and a VP40 gene expressing EBOV-Z simultaneously are inactivated and purified and then are mixed with an immunologic adjuvant to be taken as immunogens, highly immunized plasma is obtained through repeated immunization of healthy horses, IgG protein is separated and purified, then the IgG protein is subjected to pepsase digestion, an enzyme-digested product is processed by a DEAE ion-exchange chromatographic column, an eluent is collected and subjected to desalination and freeze-drying, and the horse anti-EBOV immune globulin F (ab')2 is obtained. The horse anti-EBOV immune globulin F (ab')2 is an effective drug for preventing and treating Ebola hemorrhagic fever caused by EBOV and has remarkable curative effects for critical patients infected with the EBOV; the preparation method is controlled by adopting unique technological parameters and is suitable for industrial production, and the product is safe and reliable.

This invention provides one test bar, which comprises the following steps: a, covering antibody IgM linkage single clone antibody and anti-flu hemorrhagic fever virus reset antigen multiple clone antibody two NC fiber films; b, comprising glue gold label flu hemorrhagic fever virus glass fiber film; applying film analysis and glue gold label technique to test sample flu virus antibody.

The invention relates to a method for preparing a haemorrhagic fever vaccine by culturing primary cells in a multilayer culture flask. The method comprises the following steps: anatomizing an animal to obtain the primary cells; inoculating half or one third cell of cell amount required by a spinner flask into the multilayer cell culture flask, adding proper culture solution in a hot house for culturing; and inoculating virus for culturing after the cell grows full of a single layer, obtaining virus culture solution, and preparing the vaccine after purification. The multilayer cell flask has the advantages of small amount of inoculated primary cells, large amount of the cultured cells, small occupied space, no need of a flask spinning machine and high yield.

The invention relates to a recombinant interferon lambda 4 encoded cDNA sequence which can be efficiently expressed in a prokaryotic expression system. The nucleotide sequence of the recombinant interferon lambda 4 encoded cDNA sequence is as shown in SEQ ID NO:1. The invention further provides application of the cDNA sequence in preparing a medicine for treating and/or preventing hemorrhagic fever with renal syndrome caused by hantaan viruses. The invention provides a method and application of recombinant interferon lambda 4. Escherichia coli can be concerted and expression can be induced by using a prokaryotic expression vector containing human interferon lambda 4 encoded cDNA, the optimal induction temperature of a relatively large amount of dissoluble interferon lambda 4 is 18 DEG C, the bacterium shaking speed is 120rpm, the induction time is 4 hours, and the IPTG concentration is 0.1mM. By adopting the product prepared by using the preparation method, basis is made for study on biological activity and action mechanisms of human interferon lambda 4, and the product can be also applied to medicines for treating and/or preventing hemorrhagic fever with renal syndrome caused by hantaan viruses.

The invention discloses a preparation method and application of a double-effect vaccine for the dengue fever. The invention provides a protein which is protein a) or protein b, wherein protein a) is a protein composed of an amino acid sequence as shown in a sequence 4 in a sequence table, and protein b) is a protein which has same functions as protein a) and is derived from the protein a) by subjecting the sequence 4 in the sequence table to substitution and/or deletion and/or addition of one or more amino acid residues. Experiments in the invention prove that reconstructed dengue virus non-structural protein 1 (DENV delta NS1) can be used as the vaccine; and the double-effect vaccine can protect mankind or mammals from dengue haemorrhagic fever and block propagation of the dengue virus in nature via mosquitoes.

The invention relates to the technical field of vaccine preparation, and particularly discloses an HTNV vaccine based on a VSV vector as well as a preparation method and application of the HTNV vaccine, and the HTNV recombinant VSV vaccine with immunogenicity is obtained by inserting a nucleotide sequence of HTNV envelope glycoprotein into a recombinant VSV vector plasmid to construct a recombinant plasmid and then packaging and processing the recombinant plasmid. The HTNV vaccine prepared by the invention provides a novel candidate vaccine for preventing and treating hemorrhagic fever with renal syndrome.

The invention discloses a preparation method of a fusion mutant of Ebola virus glycoprotein and matrix protein by saccharomycetes. The preparation method includes steps of 1), introducing gene for encoding the fusion mutant of Ebola virus glycoprotein and matrix protein to a receptor yeast cell to obtain the recombined yeast cell for expressing the gene; 2), orderly cultivating and breaking the recombined yeast cell to obtain the fusion mutant of Ebola virus glycoprotein and matrix protein from the broken product. The fusion mutant of Ebola virus glycoprotein and matrix protein is a recombined protein obtained by fusing an Ebola virus glycoprotein core zone reserved with an Ebola virus glycoprotein receptor bond zone and a glycan cap zone to an N terminal of the Ebola virus matrix protein. The fusion mutant of Ebola virus glycoprotein and matrix protein has a polymer structure and has galactosylated modification; therefore, the fusion mutant is potential to be a vaccine for preventing Ebola hemorrhagic fever.

The present invention discloses a polypeptide for typing hemorrhagic fever with renal syndrome caused by Hantaan virus and Seroul virus, wherein the polypeptide is selected from a polypeptide having an amino acid sequence represented by SEQ ID NO.1-SEQ ID NO.8. The invention further discloses a kit used for typing hemorrhagic fever with renal syndrome caused by Hantaan virus and Seroul virus and prepared by using the polypeptide as the effective component. According to the present invention, with the polypeptide, the detection of the clinical typing of the HTNV hemorrhagic fever with renal syndrome and the SEOV hemorrhagic fever with renal syndrome can be effectively achieved; and compared to the Western blot, the method of the present invention has the following advantages that the positive rate of the antibody in the patient serum is high, and the detection sensitivity is high.

The invention provides a reagent kit capable of simultaneously detecting virulent viruses and bacteria and a detecting method. The reagent kit is mainly in accordance with 4 pathogenic microorganismsof ebola viruses, Sinkiang hemorrhagic fever viruses, Brucella and anthrax bacillus. The reagent kit comprises a specific primer probe combination for detecting the ebola viruses, the Sinkiang hemorrhagic fever viruses, the Brucella and the anthrax bacillus, a micro-fluidic solid-phase PCR chip on which a specificity probe is fixed, and an RNase-resistant high-stability positive quality control product consisting of virus-like particles containing viral nucleic acid and thalli containing plasmid carrying the specificity nucleic acid. According to the reagent kit, simultaneous detection of theebola viruses, the Sinkiang hemorrhagic fever viruses, the Brucella and the anthrax bacillus can be realized, and the reagent kit has the advantages of being high in detection flux, high in sensitivity, high in specificity, good in repeatability, short in detection time, low in detection cost, low in operation technique requirements, not liable to pollute and the like, and has great application prospects in the field of quick simultaneous detection of various pathogenic microorganisms.

The invention is applicable to the technical field of medicines, and provides a traditional Chinese medicine composition for preventing and treating dengue virus and a preparation method thereof. Thetraditional Chinese medicine composition is prepared from plant-derived traditional Chinese medicine raw materials including an artemisia apiacea extract, a purple perilla extract and trogopterus dungthrough compatibility. The traditional Chinese medicine composition has a good prevention and treatment effect on dengue fever, dengue hemorrhagic fever and dengue heat shock syndrome caused by dengue virus infection, is long in drug effect time and good in curative effect, and particularly has a good inhibition effect on dengue fever type II viruses.

The invention provides universal Ebola virus disease immunoglobulin as well as a preparation method and application thereof. The method comprises the following steps of firstly, analyzing Zaire type,Sudan type and CotedIvoire type Ebola virus genomes, and optimizing Ebola virus GP and VP40 genetic sequences to form chimeric virus particle type sequences, so that the chimeric virus particle type sequences can completely cover main epitopes of viruses III; then, expressing, purifying and preparing Ebola chimeric virus-like particle vaccine antigens by using an insect-rhabdovirus expression system and a vaccinia virus recombinant living vector vaccine system; and finally, immunizing an animal to obtain high-immunity plasma, carrying out pepsin digestion, ammonium sulfate precipitation and chromatographic column purification to obtain the high-purity anti-Ebola virus disease immunoglobulin F(ab')2, and carrying out safety and effectiveness evaluation on the high-purity anti-Ebola virus disease immunoglobulin. The universal Ebola virus disease immunoglobulin provided by the invention can prevent and treat hemorrhagic fever caused by Ebola virus III infection, and provides a powerful tool for Ebola epidemic prevention and control.

The invention relates to a set of nucleic acids, a kit and a detection method for simultaneously detecting three viruses of Congo fever virus, Copo fever virus type 1 and Copo fever virus type 2. Thenucleic acids for simultaneously detecting three viruses by multiplex PCR comprise upstream and downstream primers of the three viruses of Congo fever virus, Copo fever virus type 1 and Copo fever virus type 2; nucleic acids for simultaneously detecting the three viruses by fluorogenic quantitative PCR comprise probes corresponding to each pathogen. The invention also establishes a relatively high-efficiency and sensitive detection method for simultaneously detecting the three viruses of Congo fever virus, Copo fever virus type 1 and Copo fever virus type 2. The method can effectively improvethe sensitivity of detection and avoid the occurrence of false negative results, and provides an effective detection method for effectively preventing hemorrhagic fever of an input virus.